10-03-05

Express Mail Label No.: EV 473991792US Date of Deposit: September 30, 2005

Atty. Docket No. 21402-018DIV (CURA 318DIV)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS:

Rastelli et al.

SERIAL NUMBER:

10/613,105

SERIAL NUMBER

10/013,103

EXAMINER:

Not Yet Assigned

FILING DATE:

July 2, 2003

ART UNIT:

1632

FOR:

METHOD OF DETECTING INFLAMMATORY LUNG DISORDERS

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Transmitted herewith for filing in the above-referenced patent application are the following documents which were previously filed on August 15, 2005. A copy of these documents are now being transmitted separately to each case listed on Schedule A, so the documents can be more easily matched up with the relevant file.

- 1. Revocation by Assignee and New Power of Attorney (2 pgs.) with attached Schedule A (4 pgs.);
- 2. Return postcard.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at 617-542-6000, Boston, Massachusetts.

The Commissioner is authorized to charge any additional fees that may be due to the undersigned's account, Deposit Account No. 50-0311, Ref. No. 21402-042 (CURA 342). A duplicate copy of this transmittal letter is enclosed herewith.

Respectfully submitted,

Ivor R. Elrifi, Reg. No. 39,529

Naomi S. Biswas. No. 38,384

Attorneys for Applicant c/o MINTZ LEVIN

Tel: (617) 542-6000 Fax: (617) 542-2241

Customer No. 55111

TRA 2078736v.1

Dated: September 30, 2005

Express Mail Label No.: EQ 128341435 US

Date of Deposit: August 15, 2005

Attorney Docket No.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ASSIGNEE:

CuraGen Corporation

SERIAL NUMBER:

See Attached Schedule A

FILING DATE:

See Attached Schedule A

FOR:

See Attached Schedule A

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

REVOCATION BY ASSIGNEE AND NEW POWER OF ATTORNEY

CuraGen Corporation, a company and owner ("Assignee") of the patents and patent applications listed on the attached Schedule A, hereby revokes any and all former powers of attorney and hereby appoints the attorneys and/or agents associated with Customer Number 55111, as Applicants' attorneys with full power of substitution and revocation to take any and all action necessary with regard to the patent application.

Please address all telephone calls to <u>Ivor R. Elrifi</u> at telephone number 617/348-1747. Please address all correspondence to Customer No. 55111.

The undersigned is authorized to act on behalf of the Assignee in the above-referenced patent application.

Respectfully submitted,

George M Yahwak, Esq.

TITLE: Director of Intellectual Property

REGISTRATION NO. 26, 824

COMPANY: CuraGen Corporation

Date: Monday, August 15, 2005

TRA 2055379v1

Schedule A

U.S. APPLICATIONS

DödketiNö.	FIRE	Rilling Dates	Арріканая No.	Assignment Reeland Frame N6s
21402-018	Method of Detecting Inflammatory Lung Disorders	May 25, 2001	09/865,812	R#
CURA 318				r# Abandoned
21402-018 DIV	Method of Detecting Inflammatory Lung Disorders	July 2, 2003	10/613,105	R#
CURA 318 DIV				F#
21402-042	Methods of Detecting and Treating Tuberous Sclerosis	Dec. 10, 2001	10/016,253	R#013294 E#0484
CURA 342	Complex Associated Disolucis		gre .	1.110404
21402-048	Therapeutic Polypeptides, Nucleic Acids Encoding Same, and methods of Use	March 19, 2003	10/391,939	R3 F#
CURA 340	TT. Dollar actidae Niveleie Acide Hacoding	Dec 2 2002	10/309.290	R#013968
Z140Z-50ZA CURA 80ZA	Same, and Methods of Use	· ·		F#0584
21402-660	Compositions and Methods for Treating T-Cell	January 31, 2005	11/047,207	R#
CURA 960	Mediated Pathological Conditions			F#
15966-557OM	Compositions and Methods of Use for a Fibroblast	May 9, 2003	10/435,087	R#015013
CURA 570M	Growth Factor			F#0343

Assignment Reeland Edme Nost	R# F#		R# F#		R# F#		R# F#	R# F#	R#013630 F#0882	R# F#	
Application NG	10/890,764 R		10/321,962 F		10/011,364 F		11/027,948 F	10/980,659 F	10/174,394 F	10/948,588 F	
Filing Date	Nov. 3, 2004		Dec. 16, 2002		November 16, 2001		December 30, 2004	Nov. 3, 2004	June 17, 2002	Sept. 23, 2004	
Table	Methods of Preventing an Treating Inflammatory Bowel Disease		Treatment of Inflammatory Bowel Disease Using Growth Factors		Treatment of Inflammatory Bowel Disease Using Growth Factors		Novel Fibroblast Growth Factor and Nucleic Acids Encoding Same	Novel Fibroblast Grown Factor and Nucleic Acids Encoding Same	Novel Fibroblast Growth Factor and Nucleic Acids Encoding Same	Antibodies to Fibroblast Growth Factor and Their Methods of Use	
Bocketino	15966-557 IBD CIP3	CURA57IBDCIP3	15966-557A IBDCIP2	CURA 57 A IBD CIP2	15966-557A IBDCIP	CURA 57 A IBDCIP	15966-557 CON CURA 57 CON	15966-557 CIP4 CURA 57CIP4	15966-557 CIP3 CURA 57 CIP3	15966-557 CIP2CON1	CURA 57 CIP2CON1

Docket No.	Lille	Eiling Date.	Application No.	Assignment Recland Frame Nos.
15966-557 CIP1 CURA 57 CIP1	Novel Fibroblast Growth Factor and Nucleic Acids Encoding Same	July 3, 2000	09/609,543	R#011317 F#0748
15966-557A CURA 57A	Treatment of Inflammatory Bowel Disease Using Growth Factors	Nov. 6, 2001	09/992,840	R#015497 F#0582
15966-557 OA CIP CURA 57 OA CIP	Fibroblast Growth Factor 20 and Methods of Use Thereof	Nov. 3, 2004	10/980,458	R# F#
15966-557 OA CURA 57 OA	Novel Fibroblast Growth Factors and Methods of Use Thereof	May 10, 2004	10/842,206	R# F#
15966-557RP CIP1 CURA 57RP CIP1	Prophylactic and Therapeutic Uses of FGF-20 in Radiation Protection	Nov. 3, 2004	10/980,695	R# F#
15966-557 RP CURA 57 RP	Therapeutic Use of G53135-05 (FGF-20) in Radiation Protection	May 10, 2004	10/842,179	R# F#
15966-557 SNP CURA 57 SNP	Compositions and Methods of Use For a Fibroblast Growth Factor	Nov. 4, 2003	10/702,126	R# F#
15966-557 PO CURA 57 PO	Methods For Diagnosing and Treatment of Conditions That Alter Phosphate Transport in Mammals	August 20, 2003	10/644,349	R#014925 F#0846
15966-557 FP CURA 57 FP	Formulations and Methods of Production of FGF-20	Nov. 3, 2004	10/980,370	R# F#

DockerNo		Filing Date	Application No.	Assignment Reel and Frame Nos
15966-557 AM CURA 57 AM	Method of Preventing and Treating Alimentary Mucositis	Nov. 3, 2004	10/980,459	R# F#
15966-577 CURA 77	Growth Factor Polypeptides and Nucleic Acids Encoding Same	Sept. 12, 2000	09/688,312	R#015523 F#0696
15966-577 CON CURA 77 CON	Growth Factor Polypeptides and Nucleic Acids Encoding Same	April 1, 2005	11/096,308	R# F#
15966-577 A CURA 77 A	Growth Factor Polypeptides and Nucleic Acids Encoding Same	October 5, 2000	09/685,330	R#011534 F#0346 Abandoned
15966-577A CIP CURA 77A CIP	Growth Factor Polypeptides and Nucleic Acids Encoding Same	October 13, 2000	09/688,312	R# F# Abandoned
15966-577A CIP2 CURA 77A CIP2	Growth Factor Polypeptides and Nucleic Acids Encoding Same	November 16, 2000	09/717,332	R# F# Abandoned
15966-577A CIP3 CURA 77A CIP3	Growth Factor Polypeptides and Nucleic Acids Encoding Same	February 2, 2001	09/775,482	R#012218 F#0294 Abandoned